A 64-year-old man with a pulmonary transplant developed diffuse verrucae vulgares of the neck. After the failure of multiple cryotherapy treatments, 3 sessions of photodynamic therapy resulted in rapid therapeutic clinical success. This moderately painful and well-tolerated treatment is reproducible and can be very useful in treating papillomavirus infections in the immunosuppressed patient.
A fast and marked improvement was noted after only 2 sessions of PDT. A third session resulted in complete clearance ( fig. 3) . No recurrence was noted 1 year after the last session of treatment.
Discussion
Viral wart treatments include local keratolytic application, topical retinoids, cryotherapy, intralesional injection of bleomycin, imiquimod, laser CO2, pulsed dye laser and intralesional immunotherapy [1] . The benefit-risk ratio in organ-transplanted patients is currently being evaluated [2] . PDT has proven to be successful in the treatment of actinic keratosis and basocellular carcinoma. At present, new indications are emerging, including verrucae vulgares.
Several studies show that protoporphyrin IX accumulation after 5-aminolevulinic acid application is not specific to tumour cells [3] . HPV-infected cells also accumulate protoporphyrin IX in a specific manner, as compared to the surrounding healthy cells [4, 5] , as demonstrated by in vivo fluorescence spectroscopy [6] . PDT therapeutic effects are due to anti-inflammatory and anti-proliferative properties activated through the release of cytotoxic radicals that destroy keratinocytes via selective apoptosis [7] .
Numerous clinical studies have demonstrated the efficiency of PDT in the treatment of viral warts of the hands [8] and feet, (recalcitrant [9] [10] [11] [12] [13] or not), including periungual warts. Several studies have shown that PDT is efficient in treating plane warts [14, 15] , including those on the face [16]. Ohtsuki et al. [17] treated verrucae vulgares on the hands and feet with a clear clinical improvement in 68.3% of the patients. This improvement was confirmed by a placebo-controlled study led by Bastuji-Garin et al. [18] . In addition, Wang et al. [19] successfully treated 42% of recalcitrant viral warts, and Chong and Kang [20] reported complete healing of recalcitrant foot verrucae vulgares after only 3 PDT sessions. Schroeter et al. [21] treated periungual warts with full clinical success in 90% of patients after a mean of 4.7 sessions. Some authors suggested the use of a keratolytic pretreatment (urea 10%, salicylic acid 10%, for 1 week) to enhance the treatment's efficiency, with complete healing in 75% of viral warts [6] . In the immunosuppressed subject, Granel-Brocard et al. [22] reported the therapeutic effect of PDT on recalcitrant warts.
The advantages of PDT are numerous. It is a safe, noninvasive technique, which yields effective therapeutic results in multiple series of patients [17, 23] . The risk of secondary infection after PDT is insignificant, and the cosmetic results are excellent [7] . The technique is particularly interesting in slow-healing subjects and acts selectively, allowing healthy surrounding skin to remain intact and functional [24] . The use of one or several fields of light enables treatment of many lesions at the same time, thus limiting the risk of wart spread and recurrence between sessions. The drawbacks are pain and local side effects such as erythema and swelling, which is generally mild and well tolerated (table 1,  table 2, table 3 ).
Immunosuppressed patients often present with extensive viral warts. Controlling the spead of these warts is of great importance because they can potentially be a source of neoplasia [25] . Our case report shows that PDT can be very efficient in the treatment of verrucae vulgares in immunosuppressed organ-transplanted patients. The technique is easy to implement, resulting in minimal side effects and reproducible results.
We think that PDT should be considered as a gold standard in the treatment of facial verrucae vulgares in immunodepressed patients.
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